杂合型血液净化在老年慢性肾衰竭患者中的临床应用效果被引量：5

Heterozygous Blood Purification in Elderly Patients With Chronic Renal Failure in Clinical Effect

下载PDF

导出

摘要目的探讨杂合型血液净化在老年慢性肾衰竭患者中的临床效果。方法选取我院进行血液净化治疗的102例慢性肾功能衰竭患者,按照血液净化方式的不同将其分为对照组和试验组,比较两组患者血液净化治疗3个月血清白蛋白、血清前白蛋白、血红蛋白和转铁蛋白的含量变化。结果实验组患者血清白蛋白、血清前白蛋白、血红蛋白和转铁蛋白的含量明显优于对照组,两组比较差异具有统计学意义(P<0.05)。结论与单纯血液净化比较,杂合型血液净化可明显改善老年慢性肾衰竭患者营养状况,进而提高其生活质量和预后水平。 Objective Discussion heterozygous clinical effect of blood purification in patients with chronic renal failure in the elderly.MethodsOur hospital blood purification therapy 102 patients with chronic renal failure patients, according to different blood purification methods will be divided into control and experimental groups were compared blood purification treatment three months serum albumin, prealbumin , hemoglobin and transferrin content changes.Results Experimental group serum albumin, prealbumin, hemoglobin and transferrin were significantly better than the control group, the difference was statistically significant （P〈0.05）.Conclusion Compared with the simple blood purification, heterozygous blood purification can significantly improve the nutritional status of elderly patients with chronic renal failure, and to improve their quality of life and prognosis level.

作者陆雯

机构地区东南大学附属中大医院血液净化中心

出处《中国卫生标准管理》 2015年第26期37-38,共2页 China Health Standard Management

关键词血液净化杂合型老年性慢性肾衰竭临床效果 Blood purification Heterozygous Senile chronic renal failure Clinical effect

分类号 R692.5 [医药卫生—泌尿科学]

引文网络
相关文献

参考文献2

1林媚,劳美珍,区景运.不同血液净化方式治疗慢性肾衰竭血液透析患者的疗效观察[J].当代医学,2013,19(13):48-49. 被引量：25
2杜艺,钱白英,柯剑婷,朱丽娟,魏玉婷,李宓.慢性肾衰竭患者血液净化治疗前后血清成纤维细胞生长因子23水平变化[J].山东医药,2014,54(43):51-54. 被引量：15

二级参考文献16

1邹贵勉,车文体,眭维国,刘作海.中药熏蒸治疗尿毒症患者顽固性瘙痒[J].中国血液净化,2006,5(1):56-57. 被引量：22
2Isakova T, Wahl P, Vargas GS, et al. Fibroblast growth factor 23 is elevated before parathyroid hormone and phosphate in chronic kidney disease[J]. Kidney Int, 2011,79(12) :1370-1378.
3Patel TV, Singh AK. Kidney disease outcomes quality initiative guidelines for bone and mineral metabolism: emerging questions [J]. Semin Nephrol, 2009,29(2) :105-112.
4Yokota H, Raposo JF, Chen A, et al. Evaluation of the role of FGF- 23 in mineral metabolism[J]. Gene Regul Syst Bio, 2009,3 (3) :131-142.
5Saito T, Fukumoto S. Fibroblast growth factor 23 ( FGF23 ) and disorders of phosphate metabolism [J]. Int J Pediatr Endocrinol, 2009,10(7) :496514.
6Gutierrez O, Isakova T, Rhee E, et al. Fibroblast growth factor-23 mitigates hyperphosphatemia but accentuates calcitriol deficiency in chronic kidney disease [ J ]. J Am Soc Nephrol, 2005,16 (7) :2205-2215.
7Isakova T, Xie HL, Barehi-Chung A, et al. Fibroblast growth fac- tor23 in patients undergoing peritoneal dialysis[J]. J Clin Am Soc Nephrol, 2011,6 ( 11 ) : 2688-2695.
8Tae Y, Nascimento MM, Shirley Y, et al. Changes in circulating biomarkers during a slngle hemodialysis session[J]. Hemodialysis International, 2013,17 ( 1 ) :59-66.
9Urena Torres P, Friedlander G, de Vernejoul MC, et al. Bone mass does not correlate with the serum fihrohlast growth factor 23 in haemodialysis patients[J]. Kidney Int, 2008,73 ( 1 ) : 102-107.
10Lornoy W, Because I, Billouw JM, et al. On-line haemodiafihra- tion. Remarkable removal of beta2- microglobulin. Long term clini- cal observation [ J ]. J Nephol Dial Transplant, 2000, 15 ( Suppl 1 ) :49-54.